Investor relations

Find relevant information about Vironova for shareholders and potential investors.


Contact investor relations

We enable the development of game changing technologies

We simplify complex processes for our customers

We remove bias from images and increase trust

We enable the development of game changing technologies

We simplify complex processes for our customers

About us

Founded in Stockholm in 2005, Vironova is a world leading partner to the global life science community in the development of novel therapies for tomorrow. By combining hardware and software solutions for advanced electron microscopy analysis, we support our partners through the whole value chain. From initial sample preparation to imaging and final analytical result, our dedicated team provide insightful and actionable data. We empower clients to make better-informed decisions, to create value and ensure safety for patients worldwide.

get to know Vironova

Watch the video and learn more about Vironova 

Market insigth and need

The life science market is shifting. Recent successes in genetic medicine have paved the way for a broader wave of therapies and next-generation technologies. As conventional therapies mature, cell and gene therapies are emerging as the future of biopharmaceuticals, representing a pivotal approach to treat previously uncurable diseases and conditions. As a result, the global cell and gene therapy market is expected to grow from 3 to 27 billion dollars by 2025.

Development of novel therapies is a highly regulated, costly and time critical process – setting high standards for secure, reliable and intuitive systems across the entire production line. Vironova is in pole position to capture value and growth opportunities in this ever-evolving landscape. Transmission electron microscopy (TEM) paired with our intelligent software and experience, is the leading method capable of producing a reliable and accurate analysis for the development of novel therapies.



Vironova´s  CEO and Founder, Mohammed Homman

Follow our journey

A great deal of things are going on in the Vironova group and in the industry, which we trendwatch and follow. Take action and follow us on our social media channels and subscribe to our newsletter to stay up to date!

You can also follow us on Mynewsdesk for relevant news updates.

The TEMperature - Subscribe to our newsletter

Our news feed

Our news feed

See all news

The problem we solve

TEM has previously been an expensive and complex practice to use in gene therapy, vaccine and drug development. At Vironova, we focus on supporting our partners by lowering technical thresholds, minimizing analytical complexity and provide business critical insights for the development of biopharmaceuticals targeting previously untreatable conditions.

We are experts in what we do and put technology and innovation at our core. From initial sample preparation to imaging and final analytical result, our dedicated team will cut time and cost to market for our clients, and ultimately create value for patients worldwide. We are on a mission to build trust in the therapies of tomorrow by making the invisible visible today.


Our Mission: We are on a mission to build trust in the therapies of tomorrow by making the invisible visible today.

The offer

Vironova provides fast and cost-effective electron microscopy services enabled by our own software and hardware. Our services are performed in the world’s only GMP-certified TEM laboratory, creating reliable and traceable results. This makes us the only company with a full-service value chain offer from start to finish.

By combining deep industry expertise and data-driven insights, we help clients solve real needs by making the subvisible accessible. With over 200 established customer relationships, Vironova is a leading partner for the life science industry. We have a strong acquisition pipeline of new clients and deep inroads with the global research community.




Two of our senior scientists analyzing images for one of our clients in the world's first and only GMP certified laboratory at Vironoca's HQ in Stockholm, Sweden.

Annual Report IR


Download Vironova AB´s
Annual Report 2020

Future plans and viability

Our vision is clear, we want to set the golden standard for safe and effective therapy development. We ensure that our clients are placing their trust in the right therapeutic candidates, by removing subjectivity from the picture. Vironova is a key niche player in the life sciences market and we are well positioned to create value in an industry with strong financial characteristics. Society is currently taking the first steps towards unleashing the full potential of gene and cell therapies. Vironova makes the journey safer by providing a clear image of the future.


Vironova Research and Innovation scientist analyzing virus image data.

Request documents

If you are an equity shareholder of Vironova, you can request our latest shareholder relevant documents by submitting this form. Make sure to use the same email in the form below as the one you use on the subscription of our newsletter for all equity shareholders. 

If you are interested in Vironova's financials but are not an equity shareholder yet, please contact

Contact us

Feel free to contacts us if you have any questions. You can always send an email directly to our investor relations team at